Yuchen Wan Zhixue Wang Ning Yang Fenye Liu
10.3389/fonc.2022.911961
Front Oncol
2022 Jul 5;12:911961.
acquired resistance camrelizumab immune checkpoint inhibitors immunotherapy multiple primary malignancies
CC BY
https://pubmed.ncbi.nlm.nih.gov/35865468/
Case Reports
PMC9294358
35865468
Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review
2022